Janux Therapeutics, Inc.

NASDAQ
JANX
paper.types.company
Rentabilité sur six mois: -47.75%
Rendement en dividendes: 0%
Secteur: Healthcare

24.24 $

0 $ 0%
22.62 $
66.83 $

paper.min_max_per_year

Calendrier des promotions Janux Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

plus de détails
The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-06-11
ISIN
US47103J1051
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 271.8 1
P/BV 2.81 6
P/E 0 0
Efficacité
Nom Signification Grade
ROA -9.57 0
ROE -10.09 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.2329 10
Debt/Ratio 0.0217 10
Debt/Equity 0.0379 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 2686.32 10
Rentabilité Ebitda, % 1397.68 10
Rentabilité EPS, % 204.67 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 24.24 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 24.77 $ 0 $ 0 $ -2.14 % 0 % 0 %
common.calendar.number_days.30d 32.23 $ 22.62 $ 26.06 $ -24.79 % 0 % 0 %
common.calendar.number_days.90d 32.6 $ 22.62 $ 33.2 $ -25.64 % 0 % 0 %
common.calendar.number_days.180d 46.39 $ 22.62 $ 63.45 $ -47.75 % 0 % 0 %
common.calendar.number_days.1y 47.26 $ 22.62 $ 66.83 $ -48.71 % 0 % 0 %
common.calendar.number_days.3y 10.91 $ 5.85 $ 66.83 $ 122.18 % 0 % 0 %
common.calendar.number_days.5y 0 $ 5.85 $ 66.83 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 5.85 $ 66.83 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 56.83 $ 22.62 $ 57.81 $ -57.35 % 0 % 0 %

Principaux propriétaires

Contenu dans l'ETF

ETFPartager, %Rentabilité pour l'année, %Commission, %
Future Tech ETF 0.25252 426.34 0.35
Principal Healthcare Innovators ETF 0.25252 618.5 0.35
0,25522,420,35

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. David Alan Campbell Ph.D. President, CEO & Director 1.04M 1960 (65 années)
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 723k 1965 (60 années)
Mr. Charles M. Winter Chief Technical Officer 590.4k 1969 (56 années)
Mr. James Pennington General Counsel N/A
Ms. Brenda Van Vreeswyk Head of Human Resources N/A
Mr. Andy Hollman Meyer Chief Business Officer N/A 1984 (41 année)
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer N/A 1986 (39 années)
Mr. Matt Whitmire Vice President of Finance
Ms. Maria Dobek Principal Accounting Officer & VP of Accounting 1989 (36 années)

Informations sur l'entreprise

Adresse: United States, La Jolla. CA, 11099 North Torrey Pines Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.januxrx.com